Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

J Nagy

Showing results (381-390 of 395) with videos related to

Pageof 40
Sort By:
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|June 17, 2020
Molecular Landscape of BRAF-Mutant NSCLC Reveals an Association Between Clonality and Driver Mutations and Identifies Targetable Non-V600 Driver MutationsMarcelo V Negrao, Victoria M Raymond, Richard B Lanman, et al.
Nature Medicine|August 14, 2019
Resistance to TRK inhibition mediated by convergent MAPK pathway activationEmiliano Cocco, Alison M Schram, Amanda Kulick, et al.
The Lancet. Oncology|May 22, 2020
First-line pembrolizumab and trastuzumab in HER2-positive oesophageal, gastric, or gastro-oesophageal junction cancer: an open-label, single-arm, phase 2 trialYelena Y Janjigian, Steven B Maron, Walid K Chatila, et al.
Cancer Discovery|September 28, 2018
Landscape of Acquired Resistance to Osimertinib in <i>EGFR</i>-Mutant NSCLC and Clinical Validation of Combined EGFR and RET Inhibition with Osimertinib and BLU-667 for Acquired <i>RET</i> FusionZofia Piotrowska, Hideko Isozaki, Jochen K Lennerz, et al.
Cancer Cell|July 11, 2018
Radiologic and Genomic Evolution of Individual Metastases during HER2 Blockade in Colorectal CancerGiulia Siravegna, Luca Lazzari, Giovanni Crisafulli, et al.
Nature Communications|March 28, 2019
Aberrant FGFR signaling mediates resistance to CDK4/6 inhibitors in ER+ breast cancerLuigi Formisano, Yao Lu, Alberto Servetto, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|July 5, 2023
Determinants of Survival with Combined HER2 and PD-1 Blockade in Metastatic Esophagogastric CancerSteven B Maron, Walid Chatila, Henry Walch, et al.
Nature Cancer|September 1, 2020
Alterations in <i>PTEN</i> and <i>ESR1</i> promote clinical resistance to alpelisib plus aromatase inhibitorsPedram Razavi, Maura N Dickler, Payal D Shah, et al.
Spinal Cord|March 30, 2011
United States (US) multi-center study to assess the validity and reliability of the Spinal Cord Independence Measure (SCIM III)K D Anderson, M E Acuff, B G Arp, et al.
Cancer Discovery|November 23, 2018
<i>EGFR</i> and <i>MET</i> Amplifications Determine Response to HER2 Inhibition in <i>ERBB2</i>-Amplified Esophagogastric CancerFrancisco Sanchez-Vega, Jaclyn F Hechtman, Pau Castel, et al.
Pageof 40

Showing results (381-390 of 395) with videos related to

Sort By:
Pageof 40
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|June 17, 2020
Molecular Landscape of BRAF-Mutant NSCLC Reveals an Association Between Clonality and Driver Mutations and Identifies Targetable Non-V600 Driver MutationsMarcelo V Negrao, Victoria M Raymond, Richard B Lanman, et al.
Nature Medicine|August 14, 2019
Resistance to TRK inhibition mediated by convergent MAPK pathway activationEmiliano Cocco, Alison M Schram, Amanda Kulick, et al.
The Lancet. Oncology|May 22, 2020
First-line pembrolizumab and trastuzumab in HER2-positive oesophageal, gastric, or gastro-oesophageal junction cancer: an open-label, single-arm, phase 2 trialYelena Y Janjigian, Steven B Maron, Walid K Chatila, et al.
Cancer Discovery|September 28, 2018
Landscape of Acquired Resistance to Osimertinib in <i>EGFR</i>-Mutant NSCLC and Clinical Validation of Combined EGFR and RET Inhibition with Osimertinib and BLU-667 for Acquired <i>RET</i> FusionZofia Piotrowska, Hideko Isozaki, Jochen K Lennerz, et al.
Cancer Cell|July 11, 2018
Radiologic and Genomic Evolution of Individual Metastases during HER2 Blockade in Colorectal CancerGiulia Siravegna, Luca Lazzari, Giovanni Crisafulli, et al.
Nature Communications|March 28, 2019
Aberrant FGFR signaling mediates resistance to CDK4/6 inhibitors in ER+ breast cancerLuigi Formisano, Yao Lu, Alberto Servetto, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|July 5, 2023
Determinants of Survival with Combined HER2 and PD-1 Blockade in Metastatic Esophagogastric CancerSteven B Maron, Walid Chatila, Henry Walch, et al.
Nature Cancer|September 1, 2020
Alterations in <i>PTEN</i> and <i>ESR1</i> promote clinical resistance to alpelisib plus aromatase inhibitorsPedram Razavi, Maura N Dickler, Payal D Shah, et al.
Spinal Cord|March 30, 2011
United States (US) multi-center study to assess the validity and reliability of the Spinal Cord Independence Measure (SCIM III)K D Anderson, M E Acuff, B G Arp, et al.
Cancer Discovery|November 23, 2018
<i>EGFR</i> and <i>MET</i> Amplifications Determine Response to HER2 Inhibition in <i>ERBB2</i>-Amplified Esophagogastric CancerFrancisco Sanchez-Vega, Jaclyn F Hechtman, Pau Castel, et al.
Pageof 40